Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company
developing targeted cellular immunotherapies for the treatment of
cancer, today announced receipt of meeting minutes from the U.S. Food
and Drug Administration (FDA) regarding a pre-Investigational New Drug
(IND) application submission meeting for Contego™ held on August 23,
2012.

“This correspondence represents a significant step in delineating the
path forward for Contego™ for the treatment of Stage IV metastatic
melanoma, and we continue to be pleased with our interactions with FDA,”
stated Anthony J. Cataldo, Chief Executive Officer of Genesis Biopharma.
“We appreciate the time FDA spent with us, and look forward to our
continuing dialogue with FDA as we advance Contego™ toward product
registration.”

Genesis Biopharma is developing Contego™, a ready-to-infuse adoptive
cellular immunotherapy (ACT) using tumor infiltrating lymphocytes (TILs)
for the treatment of Stage IV metastatic melanoma. TILs are immune cells
which have invaded a patient’s tumor in an attempt to destroy it. Dr.
Steven Rosenberg, Chief of the Surgery Branch at the National Cancer
Institute, developed the process whereby TILs are isolated directly from
the patient’s tumor, multiplied to great numbers ex vivo, and
infused into the patient to destroy the patient’s cancer. Contego™ is
based on the TIL therapy developed by Dr. Rosenberg for the treatment of
patients with Stage IV metastatic melanoma.

According to National Cancer Institute estimates, in 2012 there will be
more than 76,000 new cases of melanoma in the U.S. and more than 9,000
deaths.

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is engaged in the development and
commercialization of autologous cell therapies for the treatment of
various cancers. The Company’s lead product candidate, Contego™, is a
ready-to-infuse autologous cellular immunotherapy utilizing tumor
infiltrating lymphocytes for the treatment of patients with Stage IV
metastatic melanoma.

The foregoing announcement contains forward-looking statements that can
be identified by such terminology as “expects,” “hopes,” “potential,”
“suggests,” “bodes,” “may,” “should,” “could,” or similar expressions.
Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results to be
materially different from any future results, performance or
achievements expressed or implied by such statements. In particular,
management's expectations regarding future research, development and/or
commercial results could be affected by, among other things,
uncertainties relating to clinical trials and product development;
availability of future financing; unexpected regulatory delays or
government regulation generally; the company's ability to obtain or
maintain patent and other proprietary intellectual property protection;
and competition in general. Forward-looking statements speak only as of
the date they are made. The company does not undertake to update
forward-looking statements to reflect circumstances or events that occur
after the date the forward-looking statements are made.

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her
physician.